Drugs / DOC1021
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07288112 | Apr 2026 → Jan 2031 expected | — | Diakonos Oncology Corporation | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06805305 | Mar 2025 → Mar 2030 expected | glioblastoma | Diakonos Oncology Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-10-01 | Diakonos Oncology Corporation | Results CNS 2024 Conference Presentation: Diakonos Oncology’s Autologous Dendritic Cell Vaccine (DOC1021) Yields 93% 12-Month Survival for Glioblastoma Patients diakonosoncology.com ↗
Early analysis of the results shows no dose-limiting toxicities or concerning SAEs, and 14 of 15 evaluable patients were alive at 12 months. |
| 2024-07-15 | Diakonos Oncology Corporation | Regulatory Diakonos Oncology Receives FDA Fast Track Designation for Pancreatic Cancer Dendritic Cell Vaccine; Names Daniel D. Von Hoff, M.D. to Scientific Advisory Board diakonosoncology.com ↗
Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s unique dendritic cell vaccine (DCV) for pancreatic ductal adenocarcinoma. |
| 2024-06-03 | Diakonos Oncology Corporation | Results Diakonos Oncology CFO Anthony Baldor to Provide Corporate Update at BIO International Convention In San Diego, June 3 – 6, 2024 diakonosoncology.com ↗
Twelve month survival is currently at 90% for evaluable patients, and the therapy is well tolerated. |
| 2024-04-09 | Diakonos Oncology Corporation | Results Diakonos Oncology’s Unique Dendritic Cell Vaccine (DOC1021) Improves Survival Compared to Standard of Care in Phase 1 Trial for Glioblastoma diakonosoncology.com ↗
The median overall survival for the trial of newly diagnosed GBM has not yet been reached with 12-month survival among evaluable patients currently is 88%. |
| 2023-10-17 | Diakonos Oncology Corporation | Regulatory Diakonos Awarded FDA Fast Track Designation diakonosoncology.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOC1021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06805305 ↗ |
| Known as | dubodencel | “DOC1021 (dubodencel), a novel DC vaccine regimen integrated with SOC.” PMID 41959823 ↗ Apr 2026 |
| Action | Deplete | “The goal is to stimulate a T cell immune response that eliminates tumor cells.” NCT07288112 ↗ |
| Modality | Vaccine | “Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method” NCT06805305 ↗ |
| Route | Other | “Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses” NCT06805305 ↗ |